File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Doxorubicin for unresectable hepatocellular carcinoma. A prospective study on the addition of verapamil

TitleDoxorubicin for unresectable hepatocellular carcinoma. A prospective study on the addition of verapamil
Authors
Issue Date1990
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/28741
Citation
Cancer, 1990, v. 66 n. 8, p. 1685-1687 How to Cite?
AbstractA prospective study was conducted to assess the safety and efficacy of the addition of oral verapamil to intravenous Adriamycin (doxorubicin) for the management of patients with unresectable hepatocellular carcinoma (HCC). All 28 patients studied had histologically verified disease, and cirrhosis was present in 20 of the 21 patients with adequate tissue sampling. The overall median survival was 57 days. Chemotherapy was terminated in seven patients after one course of treatment. Partial response and complete response were noted in four patients (19%) and one patient (4.8%), respectively, among the 21 patients evaluated. Side effects related to the chemotherapy were present in all patients studied. Death from fulminating sepsis occurred in three of the 13 patients with leukopenia. Symptomatic myocardial dysfunction developed in one patient. The addition of verapamil apparently did not potentiate the tumoricidal effect of systemic Adriamycin on HCC but probably did increase its complications.
Persistent Identifierhttp://hdl.handle.net/10722/172616
ISSN
2015 Impact Factor: 5.649
2015 SCImago Journal Rankings: 3.188
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLai, ECSen_HK
dc.contributor.authorChoi, TKen_HK
dc.contributor.authorCheng, CHen_HK
dc.contributor.authorMok, FPTen_HK
dc.contributor.authorFan, STen_HK
dc.contributor.authorTan, ESYen_HK
dc.contributor.authorWong, Jen_HK
dc.date.accessioned2012-10-30T06:23:45Z-
dc.date.available2012-10-30T06:23:45Z-
dc.date.issued1990en_HK
dc.identifier.citationCancer, 1990, v. 66 n. 8, p. 1685-1687en_HK
dc.identifier.issn0008-543Xen_HK
dc.identifier.urihttp://hdl.handle.net/10722/172616-
dc.description.abstractA prospective study was conducted to assess the safety and efficacy of the addition of oral verapamil to intravenous Adriamycin (doxorubicin) for the management of patients with unresectable hepatocellular carcinoma (HCC). All 28 patients studied had histologically verified disease, and cirrhosis was present in 20 of the 21 patients with adequate tissue sampling. The overall median survival was 57 days. Chemotherapy was terminated in seven patients after one course of treatment. Partial response and complete response were noted in four patients (19%) and one patient (4.8%), respectively, among the 21 patients evaluated. Side effects related to the chemotherapy were present in all patients studied. Death from fulminating sepsis occurred in three of the 13 patients with leukopenia. Symptomatic myocardial dysfunction developed in one patient. The addition of verapamil apparently did not potentiate the tumoricidal effect of systemic Adriamycin on HCC but probably did increase its complications.en_HK
dc.languageengen_US
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/28741en_HK
dc.relation.ispartofCanceren_HK
dc.subject.meshCarcinoma, Hepatocellular - Drug Therapyen_US
dc.subject.meshDoxorubicin - Administration & Dosage - Therapeutic Useen_US
dc.subject.meshDrug Therapy, Combinationen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshLiver Neoplasms - Drug Therapyen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshProspective Studiesen_US
dc.subject.meshVerapamil - Administration & Dosage - Therapeutic Useen_US
dc.titleDoxorubicin for unresectable hepatocellular carcinoma. A prospective study on the addition of verapamilen_HK
dc.typeArticleen_HK
dc.identifier.emailFan, ST: stfan@hku.hken_HK
dc.identifier.emailWong, J: jwong@hkucc.hku.hken_HK
dc.identifier.authorityFan, ST=rp00355en_HK
dc.identifier.authorityWong, J=rp00322en_HK
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1002/1097-0142(19901015)66:8<1685::AID-CNCR2820660805>3.0.CO;2-W-
dc.identifier.pmid2169994-
dc.identifier.scopuseid_2-s2.0-0025013836en_HK
dc.identifier.volume66en_HK
dc.identifier.issue8en_HK
dc.identifier.spage1685en_HK
dc.identifier.epage1687en_HK
dc.identifier.isiWOS:A1990EE78300004-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridLai, ECS=36932159600en_HK
dc.identifier.scopusauthoridChoi, TK=7202770029en_HK
dc.identifier.scopusauthoridCheng, CH=24802108600en_HK
dc.identifier.scopusauthoridMok, FPT=6603786245en_HK
dc.identifier.scopusauthoridFan, ST=7402678224en_HK
dc.identifier.scopusauthoridTan, ESY=7402263983en_HK
dc.identifier.scopusauthoridWong, J=8049324500en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats